Publication / Source: Bioanalysis 6(16)
Authors: Hill HM
“The need to share best practices across the pharmaceutical industries is essential to ensure that the drug-development process is shortened rather than raising the bar for the competitor, resulting in prolonged development times.”
The demand for healthcare is spiraling out of control. In the USA, the healthcare budget is approximately 18% of gross domestic product (GDP)  and shows no signs of declining, in the UK the National Health Service budget for England has been capped at GB£96 billion  and is further declining. Neither scenario would appear to be a sustainable model. Diseases of aging are increasing, for example, cardiovascular disease, cancer and Alzheimer’s disease.